GREENLAND MINES LTD (GRML)
NASDAQHealth CareOther Precious MetalsSnapshot 2026-09-04
$4.76+6.25%
Close 2026-09-04 · 1-day change
NASDAQHealth CareOther Precious MetalsSnapshot 2026-09-04
QuarterlyIQ Insights · GRML
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue acquisition and merger activities to grow the company's resource holdings and technology capabilities.
Stated as a priority in 3 distinct disclosures in 2026-Q1 and 2026-Q2. The company acquired 9.9% of AnorTech and completed a merger with Neo North Star Resources in 2026-Q2. These transactions demonstrate active pursuit of M&A to expand resources and technology, delivering on stated growth strategy.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Entered into a Share Exchange Agreement to acquire 9.9% of AnorTech.”
“Completed merger with Neo North Star Resources.”
“Announced entry into a Material Definitive Agreement for acquisition.”
Develop and integrate assets across rare earth magnet materials, precious metals, and biotech to build a diversified platform.
Stated in 2 recent disclosures without specific quarterly fiscal periods. The company emphasizes building a multi-asset platform in rare earths and biotech sectors. While no direct financial metrics are available, the strategy is consistently communicated, indicating ongoing focus but limited measurable delivery in the financials.
Raise capital via registered public offerings and sales agreements to fund acquisitions, working capital, and corporate purposes.
Stated in 3 disclosures in mid to late 2026. The company raised $3.75 million through share issuance and announced a registered public offering to fund acquisitions and working capital. This shows active capital allocation efforts consistent with stated priorities.
Engage in acquisitions and share exchanges to grow resource holdings and technology capabilities, including recent acquisition of Neo North Star Resources.
Over the trailing year it converted 0.43x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
47 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.